q702
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 18, 2020 (NCT04648254)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Dendritic Cell Sarcoma, Interdigitating · Phase 1
- Erdheim-Chester Disease · Phase 1
- Esophageal Neoplasms · Phase 1/Phase 2
- Graft vs Host Disease · Phase 1
- Histiocytic Sarcoma · Phase 1
- Histiocytosis, Langerhans-Cell · Phase 1
- Histiocytosis, Sinus · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Liver Neoplasms · Phase 1/Phase 2
- Lymphangiosarcoma · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Lymphoma, T-Cell · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1
- Plasmacytoma · Phase 1
- Primary Myelofibrosis · Phase 1
- Stomach Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
MERTK inhibitor
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
CSF1R inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCn1cc(OCC(F)(F)F)c(C(=O)Nc2ccc(Oc3ccnc4cc(OC)c(OC)cc34)cn2)n1- Mol. weight
- 531.49 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314452 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07138196 | Phase 1 | Nov 17, 2025 | Qurient Co., Ltd. |
| NCT06712810 | Phase 1 | Jan 15, 2025 | Mayo Clinic |
| NCT06445907 | Phase 1 | Nov 29, 2024 | Qurient Co., Ltd., University of Texas at Houston |
| NCT05438420 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2022 | Merck, Qurient Co., Ltd. |
| NCT04648254 | Phase 1 | Nov 18, 2020 | Qurient Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qurient Co., Ltd. | For profit | 4 | 3 | 2 | 2020 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1